From the Department of Rheumatology, Keck School of Medicine/University of Southern California, Los Angeles, CA.
Yale Center for Asthma and Airway Disease, Yale University School of Medicine, New Haven, CT.
Cardiol Rev. 2022;30(1):38-43. doi: 10.1097/CRD.0000000000000358.
Systemic lupus erythematosus (SLE) is a complex connective tissue disease that can potentially affect every organ of the human body. In some cases, SLE may present with diverse cardiac manifestations including pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias. Heart disease in SLE is associated with increased morbidity and mortality. It is unclear whether traditional treatments for coronary artery disease significantly impact mortality in this population. Current therapeutic agents for SLE include glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and B cell-directed therapies. This article will provide a comprehensive review and update on this important disease state.
系统性红斑狼疮(SLE)是一种复杂的结缔组织疾病,可能会影响人体的每个器官。在某些情况下,SLE 可能表现出多种心脏表现,包括心包炎、心肌炎、瓣膜病、动脉粥样硬化、血栓形成和心律失常。SLE 中的心脏病与发病率和死亡率的增加有关。目前尚不清楚传统的冠状动脉疾病治疗方法是否会显著影响该人群的死亡率。SLE 的当前治疗药物包括糖皮质激素、羟氯喹、霉酚酸酯、硫唑嘌呤、甲氨蝶呤、环磷酰胺和 B 细胞靶向治疗。本文将对这种重要的疾病状态进行全面的回顾和更新。